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Introduction
A status report on the global burden of cancer worldwide esti-
mated lung cancer is the most frequent cancer and the leading 
cause of cancer death among males, followed by prostate and 
colorectal cancer (CRC) for incidence. While among females, 
breast cancer is the most commonly diagnosed cancer and the 
leading cause of cancer death, followed by CRC and lung can-
cer.1-4 Colorectal cancer develops through 6 independent clas-
sification systems consisting of 4 consensus molecular subtypes 
(CMS) with distinguishing features: CMS1 (Microsatellite 
Immune, 14%), hypermutated, microsatellite unstable, strong 
immune activation; CMS2 (Canonical, 37%), epithelial, chro-
mosomally unstable, marked WNT and MYC signaling activa-
tion; CMS3 (Metabolic, 13%), epithelial, evident metabolic 
dysregulation; and CMS4 (Mesenchymal, 23%), prominent 
transforming growth factor β activation, stromal invasion, and 
angiogenesis.5-7
Most cases of CRC progress from precursors known as 
colorectal polyps; the 2 common types of polyps include 
hyperplastic (HP), which do not carry a risk of developing 
into cancer, and adenomatous polyps (AP). Adenomatous 
polyps further divided into 3 main subgroups: tubular ade-
noma (TP), tubuvillous (TVP), and villus (VP). Recently, 
another type of polyp has been identified as sessile serrated 
polyps (SSA), which originate from HP and have been recog-
nized as markers for synchronous and metachronous colorec-
tal neoplasia and also premalignant lesions.8-10 The classic 
model that explains CRC development is the adenoma-carci-
noma sequence correlated with activation of the WNT sign-
aling pathway.11-13
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ABSTRACT: Aberrant activation of the WNT/CTNNB1 pathway is notorious in colorectal cancer (CRC). Here, we demonstrate that the expression 
of specific and crucial WNT signaling pathway genes is linked to disease progression in colonic adenomatous (AP) and hyperplastic (HP) polyps 
in an Iranian patient population. Thus, we highlight potential gene expression profiles as candidate novel biomarkers for the early detection of 
CRC. From a 12-month study (2016-2017), 44 biopsy samples were collected during colonoscopy from the patients with colorectal polyps and 
10 healthy subjects for normalization. Clinical and demographic data were collected in all cases, and mRNA expression of APC, CTNNB1, 
CDH1, AXIN1, and AXIN2 genes was investigated using real-time polymerase chain reaction (PCR). CTNNB1 and CDH1 expression levels 
were unaltered in AP and HP subjects, whereas mRNA expression of APC was decreased in AP contrasted with HP subjects, with a significant 
association between APC downregulation and polyp size. Although AXIN1 showed no changes between AP and HP groups, a significant 
association between AXIN1 and dysplasia grade was found. Also, significant upregulation of AXIN2 in both AP and HP subjects was detected. 
In summary, we have shown increased expression of AXIN2 and decreased expression of APC correlating with grade of dysplasia and polyp 
size. Hence, AXIN2 and APC should be explored as biomarker candidates for early detection of AP and HP polyps in CRC.
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The human genome includes 19 WNT genes, falling into 
12 conserved WNT subfamilies. WNT proteins regulate the 
proliferation of cells, and activation of the WNT signaling 
pathway as a result of genetic alterations of APC, AXIN1, and 
CTNNB1 has been found in various human cancers, including 
colon, liver, endometrium, ovary, prostate, and stomach cancers. 
The WNT signaling pathway is critical in the regulation of 
many biological processes and is one of the preliminary mecha-
nisms which confer cell proliferation and cell polarity during 
tissue homeostasis and embryonic development.14,15 In this 
way, defects in WNT signaling are often associated with can-
cers, human birth defects, and other disorders.16,17 Recently, 
studies have demonstrated that abnormal activation of the 
WNT pathway plays critical roles in tumor cell differentiation 
and proliferation.18 Activation of the WNT pathway requires 
nuclear accumulation of β-catenin (CTNNB1) and the bind-
ing of CTNNB1 to T-cell factor 4 (TCF4).15,18,19 The most 
important act of WNT/CTNNB1 signaling is the mainte-
nance of the stem cell-like character of crypt cells in the colon 
environment.20-22 WNT has a lot of subtypes and it is indefi-
nite which of them affect development of CRC.23,24 Thus, the 
investigation of WNT pathway genes in colorectal polyps as 
precursor lesions of CRC patient biopsies is essential for early 
malignant polyp detection. As there is limited information on 
the expression of WNT signaling pathway genes and different 
histological types of polyps, we aimed to focus on establishing 
mRNA expression levels of some critical WNT signaling path-
way genes, including APC, CTNNB1, AXIN1, AXIN2, and 
E-cadherin (CDH1) in AP and HP cases of the Iranian popu-




The present study was descriptive-analytical, and the investi-
gated population was chosen from cases with colorectal polyps 
that had been referred to the Taleghani Hospital, Shahid 
Beheshti University of Medical Sciences, Tehran-Iran, from 
October 2016 to April 2017. In total, 44 biopsy samples were 
collected during colonoscopy from the patients with colorectal 
polyps and 10 healthy subjects for normalization. All experi-
ments in this research were undertaken with the understanding 
and written consent of each subject, and that the study con-
forms with the Code of Ethics of the World Medical 
Association (Declaration of Helsinki), printed in the British 
Medical Journal ( July 18, 1964). This research was reviewed 
and approved by the Research Institute for Gastroenterology 
and Liver Diseases (RIGLD) ethics committee at Shahid 
Beheshti University of Medical Sciences, Tehran, Iran (No. 
1395.831).
Sample type selection was done randomly. Colorectal pol-
yps were identified at colonoscopy and confirmed by pathology, 
and biopsies of 10 healthy subjects were collected for 
normalization. Polyp-free controls were defined as those with 
no polyps identified during colonoscopy and no previous his-
tory of colorectal polyps. Exclusion criteria included any inva-
sive medical intervention within the past 6 months, a past 
history of any cancer, the presence of other GI disorders, and 
inflammatory or infectious diseases of the intestine. Biopsies 
were immediately frozen and stored in RNA Later (Qiagen, 
Hilden, Germany) at 80°C.
Demographic and medical history assessment
Demographic information including age, sex, height, weight, 
family history, diabetes mellitus history, smoking habits, physi-
cal activity, GI disease history, and alcohol consumption was 
collected via questionnaire. Medical records including colonos-
copy and pathology reports were collected directly from sur-
gery and pathology departments, respectively.
RNA extraction, and quality control and 
complementary DNA synthesis
Total RNA was extracted from all samples by QIAamp RNA 
Mini Kit (Qiagen, Hilden, Germany). RNA concentration and 
purity ratios (OD260/280, OD260/230) were measured with 
NanoDrop 1000 spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA). The integrity of RNA was deter-
mined by electrophoresis on a denaturing 1.5% agarose gel. 
Total RNA was reverse-transcribed to first-strand comple-
mentary DNA (cDNA) according to the manufacturer’s 
instructions (Thermo Scientific RevertAid Reverse 
Transcriptase 2 Step Kit, Thermo Fisher Scientific, Inc, 
Waltham, MA, USA). Briefly, 5 µL RNA (100 ng/µL) was 
incubated with 1 µL random hexamer primer (0.2 µg/µL) and 
6 µL of nuclease-free water accordingly at 65°C for 5 minutes, 
then 8 µL of the mixture was added to 12 µL reaction solution, 
containing 4 µL of 5× reaction buffer, 2 µL of dNTPs (10 mM), 
1 µL of RiboLock RNase Inhibitor (20 U/µL), and 1 µL of 
RevertAid RT (200 U/µL). The reaction was then performed 
at 25°C for 5 minutes, at 42°C for 60 minutes and at 70°C for 
5 minutes using the Eppendorf Amp PCR System (Eppendorf 
AG 22331 Hamburg, Germany). The prepared cDNA was 
then stored at −70°C.
Oligonucleotide primers and polymerase chain 
reaction
Primer pairs were designed by using the primer express soft-
ware to quantitative polymerase chain reaction (qPCR) recom-
mendations (Applied Biosystems, CA, USA), then the different 
pair of primers was also tested for their specificity using the 
database similarity search program, nucleotide-nucleotide 
BLAST (Table 1). Optimal annealing temperatures of the 
primer pairs were established via PCR, and expected PCR 
product sizes were evaluated with gradient PCR. The 
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amplification reactions were carried out in a whole volume of 
25 µL, with 1 µL of cDNA extract as a template. The PCR 
mixture consisted of 2.5 µL incubation buffer (10×), 1 µL 
MgCl2 (50 mM), 0.5 µL dNTPs (10 mM), 1 µL each primer 
(10 pmol), and 0.25 µL Taq polymerase (500 U/µL, Gene 
Fanavaran, Iran). The amplification reaction consisted of an 
initial denaturation step at 94°C for 5 minutes, followed by 30 
cycles of denaturation at 94°C for 45 seconds, primer annealing 
at 55°C to 65°C (based on primer types) for 45 seconds, and 
primer extension at 72°C for 30 seconds, with a final extension 
step at 72°C for 5 minutes.
Quantitative PCR
Real-time PCR was performed according to the manufactur-
er’s instructions (SYBR Premix Ex Taq Kit, TaKaRa Bio, Inc, 
Otsu, Japan), using a final volume of 20 µL, comprising 5 µL 
cDNA and 1 µL of 10 pmol forward and reverse primers. 
Thermal cycling conditions were as follows: an initial dena-
turation at 95°C for 30 seconds, followed by 37 cycles of 95°C 
for 5 seconds and 60°C annealing and extension for 30 seconds. 
The specificity of the PCR amplification product was con-
firmed by electrophoresis in a 2% agarose gel. Gene expression 
levels of tumor and normal tissue samples were calculated 
according to the ΔΔCt method with ΔCt = average of Ct tar-
get – average of Ctβ-actin. β-ACTIN (ACTB) mRNA was 
utilized to calculate the relative abundance of mRNA tran-
scripts. Each measurement was performed in triplicate. Fold 
change (FC) values indicate expression levels relative to normal 
tissue samples.
Statistical analysis
Data are expressed as the mean ± SD, and the statistical analysis 
was executed using the Prism software (Version 5). The analysis 
of continuous variables was performed with t-test and one-way 
analysis of variance (ANOVA), followed by an appropriate post 
hoc test. FCs of P ⩽ .05 were used as the criteria for the selec-
tion of significant differentially expressed genes.
Results
Demographic and clinical characteristics of samples
The demographic patient characterization—consisted of sex, 
age, alcohol consumption, smoking, rectal bleeding, diarrhea, 
constipation, abdominal pain, weight loss, and family history—
is interpreted in Table 2. The clinical and pathological features 
of the polyps are outlined in Table 3. Pathology reports indi-
cated that 68.2% of the lesions were adenomatous, including 
TP (43.3%), TVP (26.6%), and VP (30%); meanwhile, the HP 
and SSA comprised 64.3% and 35.7% of samples, respectively. 
The main pathological characteristics of study participants such 
as size, location, and comparison between AP and HP groups 
are shown in Table 4. Low-grade dysplasia was observed in 
76.6% of AP and 85.7% of HP cases, while high-grade dyspla-
sia was found in 23.3% of AP cases and only 14.2% of HP par-
ticipants. Samples more than 5 mm in size were observed among 
6.6% of AP and 28.6% of HP, while 93.3% of AP and 71.4% of 
HP subjects were ⩽5 mm. Most polyps were smaller than 5 mm 
with low-grade dysplasia. Moreover, about 80% of these AP and 
64.2% of HP were situated in the colon. However, these differ-
ences were found to be not statistically significant (Table 4). 
Distribution of targeted genes based on Risk Quotient (RQ) 
between HP and AP is depicted in Figure 1.
CTNNB1 mRNA expression in the colorectal 
polyps
CTNNB1 mRNA expression in colorectal polyps showed no 
expression changes in both AP and HP groups compared with 
Table 1. Primers.
PRIMER SEqUENCE LENGTH (BP) GC% SIzE (BP) ANNEALING 
TEMPERATURE (°C)
AXIN1 F 5′-TCACCCTGGGCCAGTTCAA-3′ 19 57 85 61.8
AXIN1 R 5′-CAGTCAAACTCGTCGCTCACTTTC-3′ 24 50 62.34
AXIN2 F 5′-GTCTCTACCTCATTTCCCGAGAAC-3′ 24 50 88 60.44
AXIN2 R 5′-CGAGATCAGCTCAGCTGCAA-3′ 20 55 60.46
APC F 5′-CCTCATCCAGCTTTTACATGGC-3′ 22 50 78 59
APC R 5′-GCCCGAGCCTCTTTACTGC-3′ 19 63 60
β-catenin F 5′-GTGCTATCTGTCTGCTCTAGTA-3′ 22 45.45 154 56
β-catenin R 5′-CTTCCTGTTTAGTTGCAGCATC-3′ 22 45.45 57
E-cadherin F F: 5′-TACACTGCCCAGGAGCCAGA-3′ 20 60 103 62
E-cadherin R R: 5′-TGGCACCAGTGTCCGGATTA-3′ 20 55 61
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normal participants. Also, no significant differences were found 
in expression of this gene versus location, size, and grade of 
dysplasia (Table 5).
APC mRNA expression in the colorectal polyps
APC expression in polyps was significantly decreased in AP 
subjects compared with HP polyps (P < .0001). Moreover, a 
significant association was found between APC mRNA down-
regulation and polyp size (P < .0003). No significant associa-
tion was found between polyp grade and APC mRNA 
expression level (Table 5).
AXIN1 mRNA expression in the colorectal polyps
AXIN1 expression in polyps showed no significant changes 
between AP and HP compared with the control group. Also, 
no significant association existed between AXIN1 mRNA 
expression and location of the polyp, but association between 
AXIN1 expression level and grade of dysplasia was significant 
(P < .004, Table 5).
AXIN2 mRNA expression in the colorectal polyps
AXIN2 expression in polyps displayed significantly upregula-
tion in both AP and HP colorectal polyps compared with nor-
mal participants (P < .0001). However, there was no association 
between AXIN2 upregulation and grade, location, and size of 
polyp (Table 5).
CDH1 mRNA expression in the colorectal polyps
CDH1 expression in CRC polyps showed no significant dif-
ferences in CDH1 expression in both AP and HP groups com-
pared with normal participants. However, a significant 
association between polyp location (colon/rectum) and CDH1 
expression was observed (P < .002).
Discussion
To achieve early diagnosis in CRC and improve the manage-
ment of patients, investigation into the underlying molecular 
events in different polyp subtypes is essential, and biomarker 
discovery for early malignant polyp detection is a critical step 
in CRC prevention.25,26 The WNT signaling cascade plays a 
vital role in embryogenesis and its deregulation is also impli-
cated in carcinogenesis.27,28 Colorectal cancer cases may have 
alteration in one or more of the genes of the activated WNT 
signaling pathway during colorectal carcinogenesis.29,30
In this study, we have quantified the expression levels of essen-
tial WNT signaling pathway genes including APC, CTNNB1, 
CDH1, AXIN1, and AXIN2 in colonic AP and HP cases com-
pared with age-matched control subjects. A particular strength of 
our study is that every patient withstood a complete colonoscopy, 
full visualization of the colon and different types 
of polyp removed during colonoscopies were all reviewed and 
Table 2. Demographic and clinical characteristics of the polyp cases 
in the present study.
CHARACTERISTICS VARIABLE FREqUENCY
Polyp types Adenoma 30 (68.2%)
 Hyperplastic 14 (31.8%)
All polyp types Serrated 5/14 (35.7%)
Hyperplastic 9/14 (64.3%)
Villus 9/30 (30%)
Tubular adenoma 13/30 (43.3%)
Tubule villus 8/30 (26.6%)
Dysplasia Low 34 (77.2%)
High 10 (22.7%)
Size (mm) Valid ⩽5 38 (86.3%)
Valid >5 6 (13.6%)
Location Colon 39 (88.6%)
Rectum 5 (11.3%)
Table 3. Pathological characteristics of the polyp cases in the present 
study.
CHARACTERISTICS VARIABLE FREqUENCY (%)
Sex Male 22 (50)
Female 22 (50)
Smoking Yes 8 (18.2)
No 36 (81.8)
Alcohol Yes 5 (11.3)
No 39 (88.6)
Age >50 25 (56.8)
⩽50 19 (43.1)
Blood per rectum Yes 5 (11.3)
No 44 (88.6)
Diarrhea Yes 4 (9)
No 40 (90)
Constipation Yes 6 (13.6)
No 38 (86.3)
Abdominal pain Yes 7 (15.9)
No 37 (84.1)
Weight loss Yes 4 (9)
No 40 (90)
Family history Yes 11 (25)
No 33 (75)
Total 44 (100)
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classified by the same pathologist. Critically, we demonstrate here 
that the expression level of AXIN2 was significantly increased in 
both types of AP and HP subjects (P < .0001). According to the 
relative expression levels of AXIN2 in both types of polyp, it 
could be assumed that dysregulation of AXIN2 may be occurring 
as a first step in changing intestinal tissue toward CRC initiation. 
Crucially, AXIN2 should be explored further as a biomarker for 
the characterization of AP and HP in the first step of CRC ini-
tiation. AXIN and conductin (also known as AXIN2) are 
structurally related inhibitors of Wnt/β-catenin signaling that 
promote degradation of β-catenin. Whereas AXIN is constitu-
tively expressed, conductin is a Wnt target gene implicated in 
Wnt negative feedback regulation. Therefore, AXIN2 partici-
pates in a negative feedback loop, which could serve to limit the 
duration or intensity of a Wnt-initiated signal.31-34 Our results 
confirmed those of Schaal et al,35 who also demonstrated AXIN2 
mRNA level increases in CRC initiation and progression, 
although they found no association between heightened AXIN2 






Grade Low 23 (76.6) 12 (85.7) .38
High 7 (23.3) 2 (14.2)
Size (mm) Valid ⩽5 32 (93.3) 10 (71.4) .06
Valid >5 2 (6.6) 4 (28.6)
Location Colon 24 (80) 9 (64.2) .58
Rectum/sigmoid 6 (20) 5 (35.8)
Abbreviations: HP, hyperplastic polyps; SSA, sessile serrated polyps; TP, tubular adenoma polyp; TVP, tubuvillous polyp; VP, villus polyp.
Figure 1. Expression of targeted genes (A) APC, (B) AXIN1, (C) AXIN2, (D) E-cadherin, and (E) β-catenin, in hyperplastic and adenomatous groups.
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expression and clinical parameters such as location, survival rate, 
and grade of dysplasia. However, we have observed direct and sig-
nificant association between upregulation of this target gene and 
colon location compared with rectum. Hence, we conclude that 
increased AXIN2 in those polyp cases which located in the colon 
site may have a different molecular signature and progression of 
tumor formation compared with those located in rectum site. 
Also, increased AXIN2 in both HP and AP cases indicated that 
this gene may be involved in the process of deformation and 
malignancy of the large intestinal tissue.
Kim et  al36 showed that p53 regulates GSK-3β nuclear 
localization via miR-34-mediated suppression of AXIN2 in 
CRC. Therefore, the causal link between loss of p53 function, 
increasing AXIN2, and tumorigenesis has been clearly demon-
strated by their group and ours.37 Also, Wei et al38 demonstrated 
increased levels of AXIN2 and CTNNB1 and their important 
role in the tumorigenesis and progression of ameloblastoma.37 
They declared that increasing expression level of CTNNB1 
causes its entry into the nucleus, and combining with TCF, it 
activates AXIN2 and enables AXIN2 to transcribe, causing 
abnormal expression and creating negative feedback inhibition 
in the Wnt signaling pathway.37 Also, based on previous studies, 
nuclear CTNNB1 mRNA expression accumulated and could 
be another candidate biomarker associated with invasion, 
metastasis, and poor prognosis of CRC.38,39 We achieved the 
same upregulation of AXIN2 in HP and AP cases, and in acti-
vation of the WNT signaling pathway. This upregulation of 
AXIN2 expression was significantly higher in cases over 50 years 
old (P < .0005). Hence, age could also be considered as an 
important risk factor for precursor of CRC. Neither Wei et al,38 
nor our own previous study on CRC cases observe any expres-
sion changes for CTNNB1 in both AP and HP groups com-
pared with normal participants, and there was no significant 
difference among the expression of this gene and location, size, 
and grade of dysplasia data.
This may have been due to differences in study populations, 
sample collection, and evaluating technique. We did not find 
any alterations in AXIN1 mRNA expression between AP and 
HP compared with normal control samples, which is in con-
trast to previous studies regarding reduction of AXIN1 in 
malignant behavior of lung cancers, meningeal brain tumors, 
oral squamous cell carcinoma carcinogenesis, metastasis, and 
esophageal squamous cell carcinoma.39-43 It may be concluded 
that this gene is ineffective during early steps of the changes in 
the colon tissue and CRC initiation, while other studies men-
tioned above focused on the expression of this target gene after 
tumor formation and metastasis.
Crucially, we have observed significantly reduced APC 
mRNA expression levels in adenomas compared with hyperplas-
tic participants (P < .0001). Moreover, significant associations 
existed between the APC mRNA downregulation and the size 
of the polyps (P < .0003). Inactivation of the tumor-suppressor 
gene APC, a key regulator of the WNT signaling pathway, has 
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in colorectal tumorigenesis by previous studies.44-47 Thus, other 
signaling pathways seem to play more important roles in the 
growth and development of precancerous lesions toward CRC, 
and it may be that APC gene alteration occurs in early stage of 
carcinogenesis and not in the process of polyp formation. APC 
may be altered by DNA sequence changes and/or by promoter 
hypermethylation in most colorectal carcinomas.
Finally, Jurčić et  al,48 reported no significant differences 
regarding the expression of E-cadherin in the primary tumor 
of CRC. Indeed, these results are similar to our own findings in 
that we did not observe significant differences in CDH1 
expression in both AP and HP groups compared with normal 
participants. Due to the small sample size and the inconclusive 
results obtained, further research is required to implement 
these parameters as prognostic factors.
Conclusions
This study demonstrates that CTNNB1 and CDH1 expres-
sion levels were unaltered in AP and HP subjects, whereas 
mRNA expression of APC was decreased in AP contrasted 
with HP subjects, with a significant association between APC 
downregulation and polyp size. Although AXIN1 showed no 
changes between AP and HP groups, a significant association 
between AXIN1 and dysplasia grade was found. Also, signifi-
cant upregulation of AXIN2 in both AP and HP subjects was 
detected. Overall, we propose that this panel of genes, par-
ticularly AXIN2 and APC, may be of significant usefulness as 
biomarker candidates for the early detection of AP and HP in 
CRC patients. Due to the small sample size and some nega-
tive results obtained, further research is required to imple-
ment these parameters as prognostic factors.
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